Related references
Note: Only part of the references are listed.JAK selectivity and the implications for clinical inhibition of pharmacodynamic cytokine signalling by filgotinib, upadacitinib, tofacitinib and baricitinib
Paqui G. Traves et al.
ANNALS OF THE RHEUMATIC DISEASES (2021)
Janus kinases (JAKs): The efficient therapeutic targets for autoimmune diseases and myeloproliferative disorders
Pengfei Xu et al.
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY (2020)
Design, synthesis, and pharmacological evaluation of 4-or 6-phenyl-pyrimidine derivatives as novel and selective Janus kinase 3 inhibitors
Lei Shu et al.
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY (2020)
Efficacy and safety of peficitinib (ASP015K) in patients with rheumatoid arthritis and an inadequate response to conventional DMARDs: a randomised, double-blind, placebo-controlled phase III trial (RAJ3)
Yoshiya Tanaka et al.
ANNALS OF THE RHEUMATIC DISEASES (2019)
Discovery of an Orally Available Janus Kinase 3 Selective Covalent Inhibitor
Liyang Shi et al.
JOURNAL OF MEDICINAL CHEMISTRY (2019)
Oncogenic activation of JAK3-STAT signaling confers clinical sensitivity to PRN371, a novel selective and potent JAK3 inhibitor, in natural killer/T-cell lymphoma
M. -L. Nairismagi et al.
LEUKEMIA (2018)
Discovery and structural characterization of peficitinib (ASP015K) as a novel and potent JAK inhibitor
Hisao Hamaguchi et al.
BIOORGANIC & MEDICINAL CHEMISTRY (2018)
The molecular details of cytokine signaling via the JAK/STAT pathway
Rhiannon Morris et al.
PROTEIN SCIENCE (2018)
Identification of Cyanamide-Based Janus Kinase 3 (JAK3) Covalent Inhibitors
Agustin Casimiro-Garcia et al.
JOURNAL OF MEDICINAL CHEMISTRY (2018)
Design of a Janus Kinase 3 (JAK3) Specific Inhibitor 1-(2s,5R)-5-((7H-Pyrrolo[2,3-d]pyrimidin-4-yl)amino)-2-methylpiperidin-1-y1)prop-2-en-1-one (PF-06651600) Allowing for the Interrogation of JAK3 Signaling in Humans
Atli Thorarensen et al.
JOURNAL OF MEDICINAL CHEMISTRY (2017)
The emerging safety profile of JAK inhibitors in rheumatic disease
Kevin L. Winthrop
NATURE REVIEWS RHEUMATOLOGY (2017)
Baricitinib versus Placebo or Adalimumab in Rheumatoid Arthritis
Peter C. Taylor et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Recent advances in JAK3 inhibition: Isoform selectivity by covalent cysteine targeting
Michael Forster et al.
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS (2017)
Selective JAK3 Inhibitors with a Covalent Reversible Binding Mode Targeting a New Induced Fit Binding Pocket
Michael Forster et al.
CELL CHEMICAL BIOLOGY (2016)
Development of Selective Covalent Janus Kinase 3 Inhibitors
Li Tan et al.
JOURNAL OF MEDICINAL CHEMISTRY (2015)
C5-substituted pyrido[2,3-d]pyrimidin-7-ones as highly specific kinase inhibitors targeting the clinical resistance-related EGFR(T790M) mutant
Tianfeng Xu et al.
MEDCHEMCOMM (2015)
JAK3 deregulation by activating mutations confers invasive growth advantage in extranodal nasal-type natural killer cell lymphoma
A. Bouchekioua et al.
LEUKEMIA (2014)
JAK/STAT signaling in hematological malignancies
W. Vainchenker et al.
ONCOGENE (2013)
JAK and STAT Signaling Molecules in Immunoregulation and Immune-Mediated Disease
John J. O'Shea et al.
IMMUNITY (2012)
Newly described activating JAK3 mutations in T-cell acute lymphoblastic leukemia
T. Bains et al.
LEUKEMIA (2012)
Inhibition of JAK kinases in patients with rheumatoid arthritis: scientific rationale and clinical outcomes
Richard J. Riese et al.
BEST PRACTICE & RESEARCH IN CLINICAL RHEUMATOLOGY (2010)
Discovery of CP-690,550: A Potent and Selective Janus Kinase (JAK) Inhibitor for the Treatment of Autoimmune Diseases and Organ Transplant Rejection
Mark E. Flanagan et al.
JOURNAL OF MEDICINAL CHEMISTRY (2010)
JAK3: A two-faced player in hematological disorders
Melanie G. Cornejo et al.
INTERNATIONAL JOURNAL OF BIOCHEMISTRY & CELL BIOLOGY (2009)
Activating alleles of JAK3 in acute megakaryoblastic leukemia
Denise K. Walters et al.
CANCER CELL (2006)
Share Paper
